![Schizophrenia Drug Market Size, Industry Analysis By Type (Paranoid Schizophrenia, Hebephrenic Schizophrenia, Catatonic Schizophrenia and Undifferentiated Schizophrenia), By Therapeutic Class {Second-Generation Antipsychotics [Risperdal (Risperidone), Invega (Paliperidone), Zyprexa (Olanzapine), Geodon (Ziprasidone), Seroquel (Quetiapine), Latuda (Lurasidone)], Third-Generation Antipsychotics and others}, By Route of Administration (Oral and Injectables) – Global, Trends, Share And Forecast 2023-2030](https://www.infinitivedataexpert.com/assets/img/infinitive-Report-Cover.png)
All updated as on -
The global Schizophrenia Drug market is expected to reach USD 11.91 billion by 2030, at a CAGR of 3.9% during the forecast period 2022 to 2030.
People with schizophrenia have a skewed perception of reality. Hallucinations, delusions, and severely aberrant cognition and behaviour are common symptoms that can have a devastating impact on a person's ability to function in daily life. This disease affects both sexes equally, while probably manifesting earlier in men. Patients with schizophrenia are more likely to die at a young age because of the incidence of co-occurring disorders including diabetes and heart disease. The first signs typically appear in early adulthood. Males typically experience the onset of symptoms in their late teens or early 20s, whereas females typically experience the onset of symptoms in their 20s and 30s. Medication is available for those suffering with schizophrenia. These drugs correct a chemical imbalance in the brain. There are three main categories of antipsychotic drugs used to manage schizophrenia: second-generation antipsychotics, third-generation antipsychotics, and others. Depending on the method of administration, it can be taken orally or injected.
Report Coverage
Global Schizophrenia Drug research report categorizes the market for global based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. Global Schizophrenia Drug report analyses the key growth drivers, opportunities, and challenges influencing the global market. Recent market developments and Schizophrenia Drug competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key Schizophrenia Drug market players and analyses their core competencies in each global market sub-segments.
The primary forces driving the growth of the schizophrenia market are high unmet medical demands and increased expenditure for research and development. Novel, cutting-edge drugs with improved efficacy and safety profiles have contributed to the expansion of the schizophrenia market. It is anticipated that the rise of the schizophrenia market will be fueled in part by partnerships and cooperation between pharmaceutical companies, academic institutions, and government agencies to research and sell novel therapies. As a result, this is what's pushing the market's CAGR higher. Advances in neuroimaging, genetics, and neurochemistry have improved our understanding of the root causes of schizophrenia and paved the way for the development of novel, more effective treatments. Public-private collaborations, investments in R&D, and supportive reimbursement policies in many countries are also contributing to the industry's growth.
The worldwide market for schizophrenia medications is broken down by therapeutic class into second-generation antipsychotics and third-generation antipsychotics. Among them, the segment representing products of the second generation is expected to hold the biggest market share during the projection period. Since second-generation antipsychotics are more efficient and safer than first-generation medications, they stand to make the most money during the projected period. The need to address the major adverse effects of first-generation medications, often known as atypical antipsychotics, drove the creation of second- and third-generation therapies.
Key Points Covered in the Report
Competitive Environment:
The research provides an accurate study of the major organisations and companies operating in the global Schizophrenia Drug market, along with a comparative evaluation based on their product portfolios, corporate summaries, geographic reach, business plans, Schizophrenia Drug market shares in specific segments, and SWOT analyses. A detailed analysis of the firms' recent news and developments, such as product development, inventions, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and other activities, is also included in the study. This makes it possible to assess the level of market competition as a whole.
List of Major Market Participants
Primary Target Market
Market Segment:
This study forecasts global, regional, and country revenue from 2019 to 2030. Spherical Insights has segmented the global Schizophrenia Drug market based on the below-mentioned segments:
Global Schizophrenia Drug Market, By Type
Global Schizophrenia Drug market, By Route of Administration
Global Schizophrenia Drug market, Regional Analysis
People with schizophrenia have a skewed perception of reality. Hallucinations, delusions, and severely aberrant cognition and behaviour are common symptoms that can have a devastating impact on a person's ability to function in daily life. This disease affects both sexes equally, while probably manifesting earlier in men. Patients with schizophrenia are more likely to die at a young age because of the incidence of co-occurring disorders including diabetes and heart disease. The first signs typically appear in early adulthood. Males typically experience the onset of symptoms in their late teens or early 20s, whereas females typically experience the onset of symptoms in their 20s and 30s. Medication is available for those suffering with schizophrenia. These drugs correct a chemical imbalance in the brain. There are three main categories of antipsychotic drugs used to manage schizophrenia: second-generation antipsychotics, third-generation antipsychotics, and others. Depending on the method of administration, it can be taken orally or injected.
Report Coverage
Global Schizophrenia Drug research report categorizes the market for global based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. Global Schizophrenia Drug report analyses the key growth drivers, opportunities, and challenges influencing the global market. Recent market developments and Schizophrenia Drug competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key Schizophrenia Drug market players and analyses their core competencies in each global market sub-segments.
The primary forces driving the growth of the schizophrenia market are high unmet medical demands and increased expenditure for research and development. Novel, cutting-edge drugs with improved efficacy and safety profiles have contributed to the expansion of the schizophrenia market. It is anticipated that the rise of the schizophrenia market will be fueled in part by partnerships and cooperation between pharmaceutical companies, academic institutions, and government agencies to research and sell novel therapies. As a result, this is what's pushing the market's CAGR higher. Advances in neuroimaging, genetics, and neurochemistry have improved our understanding of the root causes of schizophrenia and paved the way for the development of novel, more effective treatments. Public-private collaborations, investments in R&D, and supportive reimbursement policies in many countries are also contributing to the industry's growth.
The worldwide market for schizophrenia medications is broken down by therapeutic class into second-generation antipsychotics and third-generation antipsychotics. Among them, the segment representing products of the second generation is expected to hold the biggest market share during the projection period. Since second-generation antipsychotics are more efficient and safer than first-generation medications, they stand to make the most money during the projected period. The need to address the major adverse effects of first-generation medications, often known as atypical antipsychotics, drove the creation of second- and third-generation therapies.
| REPORT ATTRIBUTES | DETAILS |
|---|---|
| Study Period | 2017-2030 |
| Base Year | 2020 |
| Forecast Period | 2022-2030 |
| Historical Period | 2017-2019 |
| Unit | Value (USD Billion) |
| Key Companies Profiled | Johnson & Johnson Services, Inc., Bristol-Myers Squibb Company, Otsuka Holdings Co. Ltd., AstraZeneca, Eli Lilly and Company, Alkermes, Sumitomo Dainippon Pharma Co. Ltd., Pfizer Inc., VANDA PHARMACEUTICALS, Mayo Foundation for Medical Education and Research (MFMER), Allergan, H. Lundbeck A/S, AVINEURO PHARMACEUTICALS, Gedeon Richter plc, Astellas Pharma Inc., Novartis AG, AbbVie Inc., PsychoGenics Inc., Merz Pharma |
| Segments Covered | • By Product |
| Customization Scope | Free report customization (equivalent to up to 3 analyst working days) with purchase. Addition or alteration to country, regional & segment scope |
Key Points Covered in the Report
- Market Revenue of Schizophrenia Drug Market from 2021 to 2030.
- Market Forecast for Schizophrenia Drug Market from 2021 to 2030.
- Regional Market Share and Revenue from 2021 to 2030.
- Country Market share within region from 2021 to 2030.
- Key Type and Application Revenue and forecast.
- Company Market Share Analysis, Schizophrenia Drug competitive scenario, ranking, and detailed company
profiles. - Market driver, restraints, and detailed COVID-19 impact on Schizophrenia Drug
Market
Competitive Environment:
The research provides an accurate study of the major organisations and companies operating in the global Schizophrenia Drug market, along with a comparative evaluation based on their product portfolios, corporate summaries, geographic reach, business plans, Schizophrenia Drug market shares in specific segments, and SWOT analyses. A detailed analysis of the firms' recent news and developments, such as product development, inventions, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and other activities, is also included in the study. This makes it possible to assess the level of market competition as a whole.
List of Major Market Participants
- Johnson & Johnson Services, Inc.
- Bristol-Myers Squibb Company
- Allergan
- H. Lundbeck A/S
- Otsuka Holdings Co. Ltd.
- AstraZeneca
- Eli Lilly and Company
- Alkermes
- Sumitomo Dainippon Pharma Co. Ltd.
- Pfizer Inc.
- VANDA PHARMACEUTICALS
- Mayo Foundation for Medical Education and Research (MFMER)
- AVINEURO PHARMACEUTICALS
- Gedeon Richter plc
- Astellas Pharma Inc.
- Novartis AG
- AbbVie Inc.
- PsychoGenics Inc.
- Merz Pharma
Primary Target Market
- Market Players of Schizophrenia Drug
- Investors
- End-users
- Government Authorities
- Consulting And Research Firm
- Venture capitalists
- Third-party knowledge providers
- Value-Added Resellers (VARs)
Market Segment:
This study forecasts global, regional, and country revenue from 2019 to 2030. Spherical Insights has segmented the global Schizophrenia Drug market based on the below-mentioned segments:
Global Schizophrenia Drug Market, By Type
- Paranoid schizophrenia
- Hebephrenic schizophrenia
- Catatonic schizophrenia
- Undifferentiated schizophrenia
Global Schizophrenia Drug market, By Route of Administration
- Oral
- Injectable
Global Schizophrenia Drug market, Regional Analysis
- Europe: Germany, Uk, France, Italy, Spain, Russia, Rest of Europe
- The Asia Pacific: China,Japan,India,South Korea,Australia,Rest of Asia Pacific
- South America: Brazil, Argentina, Rest of South America
- Middle East & Africa: UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa
About This Research
You will get in-depth and extensive schizophrenia drug market market research and competitor analysis for your business to help you develop more profound insights into the schizophrenia drug market Market.
Through INFINITIVE Data Expert is a professional Market Research services, I will identify the schizophrenia drug market market size, demand & opportunities, growth rate, and target audience with a comprehensive analysis of your competitors.